NASDAQ: OBIOOrchestra Biomed Holdings Inc Stock
$2.97+0.44 (+17.39%)
Updated Apr 30, 2025
OBIO Price
$2.97
Fair Value Price
$0.50
Market Cap
$113.79M
52 Week Low
$2.43
52 Week High
$8.87
P/E
-1.79x
P/B
3.45x
P/S
55.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.64M
Earnings
-$61.02M
Gross Margin
92.3%
Operating Margin
-2,313.27%
Profit Margin
-2,313.3%
Debt to Equity
1.31
Operating Cash Flow
-$51M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OBIO Overview
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OBIO's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OBIO
Ranked#435 of 462
Ranked#435 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important OBIO news, forecast changes, insider trades & much more!
OBIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OBIO ($2.97) is overvalued by 495.57% relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OBIO ($2.97) is not significantly undervalued (495.57%) relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OBIO due diligence checks available for Premium users.
Valuation
OBIO fair value
Fair Value of OBIO stock based on Discounted Cash Flow (DCF)
Price
$2.97
Fair Value
$0.50
Overvalued by
495.57%
OBIO ($2.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OBIO ($2.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.79x
Industry
-162.28x
Market
29.18x
OBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.45x
Industry
4.45x
OBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OBIO's financial health
Profit margin
Revenue
$253.0k
Net Income
-$16.2M
Profit Margin
-6,385.4%
OBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.2M
Liabilities
$43.2M
Debt to equity
1.31
OBIO's short-term assets ($69.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OBIO's short-term assets ($69.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.5M
Investing
-$3.8M
Financing
$13.9M
OBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OBIO vs Biotech Stocks
Orchestra Biomed Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.